share_log

Ginkgo Bioworks | 10-K: FY2023 Annual Report

SEC ·  Mar 1 11:40

Summary by Futu AI

Ginkgo Bioworks, a leading horizontal platform for cell programming, reported a stable Cell Engineering revenue of $143.5 million in 2023, nearly unchanged from the previous year. However, the company experienced a significant decrease in Biosecurity revenue, which dropped by $226.1 million due to reduced demand for COVID-19 testing products and services. The company's total revenue for the year was $251.5 million, a substantial decline from $477.7 million in 2022. Research and Development expenses saw a decrease of $472 million, primarily due to a reduction in stock-based compensation expense. General and Administrative expenses also decreased by $1.04 billion for the same reason. Ginkgo faced a $96.2 million impairment related to the exit of a Zymergen facility. Interest income increased by $37 million, attributed to higher interest rates on cash...Show More
Ginkgo Bioworks, a leading horizontal platform for cell programming, reported a stable Cell Engineering revenue of $143.5 million in 2023, nearly unchanged from the previous year. However, the company experienced a significant decrease in Biosecurity revenue, which dropped by $226.1 million due to reduced demand for COVID-19 testing products and services. The company's total revenue for the year was $251.5 million, a substantial decline from $477.7 million in 2022. Research and Development expenses saw a decrease of $472 million, primarily due to a reduction in stock-based compensation expense. General and Administrative expenses also decreased by $1.04 billion for the same reason. Ginkgo faced a $96.2 million impairment related to the exit of a Zymergen facility. Interest income increased by $37 million, attributed to higher interest rates on cash holdings. Losses on equity method investments decreased by $41.1 million, while losses on investments increased slightly by $1.5 million. The company's net loss for the year was $892.9 million, an improvement from the $2.1 billion loss in 2022. Ginkgo's future plans include expanding its offerings of biomonitoring and bioinformatic support services through domestic and international partnerships.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.